#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Internal Medicine / 2019 - 5

Multimodal treatment of thymic carcinoid: a case report

Czech version

Authors: Radka Cahajlová 1;  Mária Černá 1;  Soňa Kiňová 2
Authors‘ workplace: Oddelenie klinickej onkológie Kliniky pneumológie a funkčnej diagnostiky SZU a UNB, Nemocnica Ružinov, Bratislava, Slovenská republika 1;  I. interná klinika LF UK a UNB, Nemocnica Staré mesto, Bratislava, Slovenská republika 2
Published in: Vnitř Lék 2019; 65(5): 363-368
Category: Case reports

Overview

Thymic carcinoid account for cca 0.4 % of all carcinoid tumors in the body [1]. As compared to other neuroendocrinne tumors, high rates of reccurences after surgery, more aggressive behaviour and relatively high rates of paraneoplastic syndromes are characteristic for thymic carcinoid. The mainstay of treatment is radical surgery [2–4]. Therapy of locally advanced and metastatic stages is influenced by other neuroendocrinne tumors´guidelines. We present a case report of patient with locally advanced, atypical thymic carcinoid, treated with different modalities, including newer procedures like peptide radionuclide receptor therapy (PRRT).

Keywords:

peptide radionuclide receptor therapy – somatostatine analogues – thymic carcinoid

Sources
  1. Litvak A, Pietanza MC. Bronchial and Thymic Carcinoid Tumors.Hematol Oncol Clin North Am 2016;30(1):83–102. Dostupné z DOI: <http://dx.doi.org/10.1016/j.hoc.2015.09.003>.
  2. Filosso PL, Actis Dato GM, Ruffini E et al. Multidisciplinary treatment of advanced thymic neuroendocrine carcinoma (carcinoid): Report of a succesful case and review of the literature[online]. J Thorac Cardiovasc Surg 2004; 127(4): 1215–1219. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jtcvs.2003.09.058>.
  3. Mikhail M, Mekhail Y, Mekhail T Thymic neoplasm: A clinical Update [online]. Curr Oncol Rep 2012; 14(4): 350–358. Dostupné z DOI: <http://dx.doi.org/10.1007/s11912–012–0246–8>.
  4. Gielda BT, Peng R, Colamen JL et al. Treatment of Early stage thymic tumors: surgery and radiotion therapy. Curr Treat Options Oncol 2008; 9(4–6): 259–268. Dostupné z DOI: <http://dx.doi.org/10.1007/s11864–008–0080–2>.
  5. Chaer R, Massad MG, Evans A et al. Primary neuroendocrine tumors of the thymus. Ann Thorac Surg 2002; 74(5): 1733–1740.
  6. Öberg K, Hellman P, Ferolla P et al. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Pracstise Guidelines for diagnosis, treatment and follow up. Ann Oncol 2012; 23(Suppl 7): vii120–123. Dostupné z DOI: <http://dx.doi.org/10.1093/annonc/mds267>.
  7. Filosso PL, Ruffini E, Solidoro P et al. Neuroendocrine tumors of the thymus. J Thorac Dis 2017; 9(Suppl 15): S1484-S1490. Dostupné z DOI: <http://dx.doi.org/10.21037/jtd.2017.10.83>.
  8. Tamura M, Ohta Y, Oda M et al. Thymic carcinoid Tumor. Jpn J Thorac Cardiovasc Surg 2003; 51(1): 29–31. Dostupné z DOI: <http://dx.doi.org/10.1007/s11748–003–0063-y>.
  9. Srirajaskanthan R, Toubanakis C, Dusmet M et al. A review of thymic tumours. Lung Cancer 2008; 60(1): 4–13. Dostupné z DOI: <http://dx.doi.org/10.1016/j.lungcan.2008.01.014>.
  10. van Essen M, Krenning EP, Bakker WH et al. Peptide receptor radionuclide therapy with 177 LU-octreotate in patients with foregit carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging 2007; 34(8): 1219–1227. Dostupné z DOI: <http://dx.doi.org/10.1007/s00259–006–0355–4>.
  11. Tomišková M. NEN plic a thymu. In: Sedláčová E, Bajčiová V (eds.) Neuroendokrinní nádory. Maxdorf: Praha 2016: 180–202. ISBN 978–80–7345–468–5
  12. Girard N. Neuroendocrine tumors of the thymus: the oncologist point of view. J Thorac Dis. 2017; 9(Suppl 15): S1491-S1500. Dostupné z DOI: <http://dx.doi.org/10.21037/jtd.2017.08.18>.
  13. Crona J, Björklund P, Welin S et al. Treatment, prognostic markers and survival in thymic neuroendocrine tumours. A study from a single tertiary referral centre. Lung Cancer 2013; 79(3): 289–293. Dostupné z DOI: <http://dx.doi.org/10.1016/j.lungcan.2012.12.001>.
  14. Song Z, Zhang Y. Primary neuroendocrine tumors of the thymus: Clinical review of 22 cases. Oncol Lett 2014; 8(5): 2125–2129. Dostupné z DOI: <http://dx.doi.org/10.3892/ol.2014.2490>.
  15. Dham A, Truskinovsky AM, Dudek AZ Thymic Carcinoid Responds to Neoadjuvant Therapy with Sunitinib and Octreotide. A Case report. J Thorac Oncol 2008; 3(1): 94–97. Dostupné z DOI: <http://dx.doi.org/10.1097/JTO.0b013e31815eb7a2>.
  16. Rinke A, Müller HH, Schade-Brittinger Cet al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009; 27(28): 4656–4663. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2009.22.8510>.
  17. Caplin ME, Pavel M, Cwikla JB et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371(3): 224–233. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1316158>.
  18. Bongiovanni A, Recine F, Riva N et al. Outcome analysis of first-line Somatostatin Analog Treatment in Metastatic pulmonary Neuroendoctrine Tumors and prognostic Significance of 18 FDG-PET/CT. Clinical Lung Cancer 2017; 18(4): 415–420. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cllc.2016.11.004>.
  19. Zogala D. Terapie pomocí otevřených zářičü. In: Sedláčová E, Bajčiová V (eds) Neuroendokrinní nádory. Maxdorf: Praha 2016: 156–164. ISBN 978–80–7345–468–5.
  20. Imhof A, Brunner P, Marincek N et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011; 29(17): 2416–2423. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2010.33.7873>.
  21. Thapa P, Parghane R, Basu S. 177 Lu- DOTATE Peptide Receptor radionuclide Therapy in Metastatic or Advanced and Inoperable Primary Neuroendocrine Tumors of rare Sites. World J Nucl Med 201716(3):223–228. Dostupné z DOI: <http://dx.doi.org/10.4103/1450–1147.207283>.
  22. Puranik AD, Kulkarni HR, Singh A et al. 8-year survival with a metastatic thymic neuroendocrine tumor: emphasision redefining “treatment objectives” using personalized peptide receptor radionuclide therapy with 177LU- an 90Y-labeled somatostatin analogs. AACE Clinical Case Rep 2015; 1(2): e131-e135. Dostupné z DOI: <http://dx.doi.org/10.4158/EP14354.CR>.
  23. Yao JC et al. Everolimus for the treatment of advanced, on-functional neuroendorcrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-contralled, phasy 3 study. Lancet 2016; 387(10022): 968–977. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(15)00817-X>.
  24. Zhu S, Wang ZT, Liu WZ et al. Invasive atypical thymic carcinoid: three case reports and literature review. Onco Targets Ther 2016; 9: 6171–6176. Dostupné z DOI: <http://dx.doi.org/10.2147/OTT.S109693>.
Labels
Diabetology Endocrinology Internal medicine
Limited ambulatory night sleep testing in patients with a suspicion of sleep apnoea syndrome: Is its indication tenable?
Surgical treatment of chronic thromboembolic pulmonary hypertension
Communication with cancer patient
Compliance with ethical rules for scientific publishing in biomedical Open Access journals indexed in Journal Citation Reports
Nontuberculous mycobacterial disease: a case report-based review
Use of idarucizumab in clinical practice: a case report
Otto Kahler and his family: II. Ripening years in Prague
Article was published in

Internal Medicine

Issue 5
2019 Issue 5
Most read in this issue
Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#